Avastin vs. Lucentis
Avastin vs. Lucentis Treatment for Wet Macular Degeneration
Genentech USA, Inc.: Lucentis
Regeneron Challenges Genentech's Lucentis
Regeneron Pharmaceuticals won approval for its macular degeneration drug Eylea, putting the drug into competition with Genentech’s Lucentis and Avastin.
read more: Regeneron Challenges Genentech's Lucentis
Novartis cuts Lucentis price amid growing pressure
Novartis has been forced to cut the Swiss price of its eye drug Lucentis by 30% after sharp negotiations with the government.
read more: Novartis cuts Lucentis price amid growing pressure
BURKHALTER FAIT RECULER NOVARTIS
Novartis ne le claironne pas. Mais depuis le début de ce mois, le géant pharmaceutique accorde un rabais de 30% sur le Lucentis, le seul traitement officiellement reconnu contre la dégénérescence maculaire humide liée à l'âge (DMLA).
lire la suite: BURKHALTER FAIT RECULER NOVARTIS
When cheaper isn't better: The case of Avastin, Lucentis and wet AMD
To make a long story short, Avastin is a highly-effective anti-cancer drug. Lucentis is basically the same drug, but it's indicated for an ophthalmic condition: wet age-related macular degeneration. Since Lucentis is injected in the eye only a little bit is needed.
read more: When cheaper isn't better: The case of Avastin, Lucentis and wet AMD
Lucentis vs Avastin study may feature at May 1-5 congress
Results of the so-called CATT study comparing Roche (ROG.VX) and Novartis's (NOVN.VX) eye drug Lucentis with low doses of cancer treatment Avastin may be presented at a medical meeting in early May.
read more: Lucentis vs Avastin study may feature at May 1-5 congress
Genentech Offers Secret Rebates for Eye Drug
Genentech has begun offering secret rebates to eye doctors as an apparent inducement to get them to use more of the company's expensive drug Lucentis rather than a less costly alternative.
read more: Genentech Offers Secret Rebates for Eye Drug
Bevacizumab vs ranibizumab for age-related macular degeneration:
1-year outcomes of a prospective, double-masked randomised clinical trial
read more: Bevacizumab vs ranibizumab for age-related macular degeneration:
BUSM Researchers Find Cancer Drug as Effective and Less Costly than Standard Macular Degeneration Treatment
Investigators from BUSM and the VA Boston Healthcare System have shown, at the six month mark in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
read more: BUSM Researchers Find Cancer Drug as Effective and Less Costly than Standard Macular Degeneration Treatment